HSBC Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $13
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Rajesh Kumar has initiated coverage on Teva Pharmaceutical Industries (NYSE:TEVA) with a Buy rating and set a price target of $13.
December 18, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HSBC analyst Rajesh Kumar initiated coverage on Teva Pharmaceutical Industries with a Buy rating and a price target of $13.
The initiation of coverage by HSBC with a Buy rating is a positive signal for investors, suggesting confidence in Teva's future performance. The price target of $13 indicates a potential upside from the current trading price, which could lead to increased investor interest and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100